RU2487873C2 - 5-замещенные индазолы в качестве ингибиторов киназы - Google Patents

5-замещенные индазолы в качестве ингибиторов киназы Download PDF

Info

Publication number
RU2487873C2
RU2487873C2 RU2009149696/04A RU2009149696A RU2487873C2 RU 2487873 C2 RU2487873 C2 RU 2487873C2 RU 2009149696/04 A RU2009149696/04 A RU 2009149696/04A RU 2009149696 A RU2009149696 A RU 2009149696A RU 2487873 C2 RU2487873 C2 RU 2487873C2
Authority
RU
Russia
Prior art keywords
indazol
triazol
carboxamide
benzyl
indazole
Prior art date
Application number
RU2009149696/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009149696A (ru
Inventor
Ирини АКРИТОПОУЛОУ-ЗАНЗЕ
Брайан Д. УЭЙКФИЛД
Хельмут Мак
Шон К. ТЕРНЕР
Алан Ф. ГАСИКИ
Виджая Дж. ГРАСИАС
Кэти Саррис
Дуглас М. КАЛВИН
Мелисса Дж. МИЧМЕРХУЗЕН
Ци ШУАЙ
Джиоти Р. ПАТЕЛ
Маргарета БАККЕР
Николь ТОЙШ
Эрик Ф. ДЖОНСОН
Питер Дж. КОВАР
Стивен В. ДЬЮРИК
Эндрю Дж. ЛОНГ
Анил ВАСУДЕВАН
Адриан ХОБСОН
ДЖОН МУР Найджел СТ.
Лу ВАН
Дон ДЖОРЖ
Бицинь ЛИ
Кристин ФРАНК
Original Assignee
Эбботт Лэборетриз
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Лэборетриз, Эбботт Гмбх Унд Ко. Кг filed Critical Эбботт Лэборетриз
Publication of RU2009149696A publication Critical patent/RU2009149696A/ru
Application granted granted Critical
Publication of RU2487873C2 publication Critical patent/RU2487873C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
RU2009149696/04A 2007-06-08 2008-06-04 5-замещенные индазолы в качестве ингибиторов киназы RU2487873C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93396007P 2007-06-08 2007-06-08
US60/933,960 2007-06-08
PCT/US2008/065727 WO2008154241A1 (en) 2007-06-08 2008-06-04 5-heteroaryl substituted indazoles as kinase inhibitors

Publications (2)

Publication Number Publication Date
RU2009149696A RU2009149696A (ru) 2011-07-20
RU2487873C2 true RU2487873C2 (ru) 2013-07-20

Family

ID=39951673

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009149696/04A RU2487873C2 (ru) 2007-06-08 2008-06-04 5-замещенные индазолы в качестве ингибиторов киназы

Country Status (13)

Country Link
EP (1) EP2167491A1 (ja)
JP (2) JP5451602B2 (ja)
KR (1) KR20100032886A (ja)
CN (1) CN101790526A (ja)
AU (1) AU2008262038A1 (ja)
BR (1) BRPI0811065A2 (ja)
CA (1) CA2689117A1 (ja)
IL (1) IL202318A0 (ja)
MX (1) MX2009013213A (ja)
RU (1) RU2487873C2 (ja)
SG (1) SG182187A1 (ja)
WO (1) WO2008154241A1 (ja)
ZA (1) ZA200908624B (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725979C2 (ru) * 2014-06-25 2020-07-08 Ф. Хоффманн-Ля Рош Аг ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
WO2008156757A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
WO2009028543A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
MY152271A (en) 2008-02-21 2014-09-15 Merck Sharp & Dohme Novel compounds that are erk inhibitors
AR071780A1 (es) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
ES2548141T3 (es) * 2008-11-20 2015-10-14 Glaxosmithkline Llc Compuestos químicos
HUE028259T2 (en) 2009-08-10 2016-12-28 Samumed Llc Inhibitors of Wnt signaling signal indazole and their therapeutic use
CN104546846B (zh) 2009-12-21 2017-04-12 萨穆梅德有限公司 1H‑吡唑并[3,4‑b]吡啶及其治疗应用
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
KR101233082B1 (ko) 2010-02-25 2013-02-14 주식회사 이큐스앤자루 신규한 이미다졸피라진 유도체 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스 치료용 약학적 조성물
EP2542549B1 (en) * 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
RU2012136643A (ru) * 2010-04-28 2014-06-10 Дайити Санкио Компани, Лимитед [5,6]- гетероциклическое соединение
US8877795B2 (en) 2010-05-07 2014-11-04 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
PL2655357T3 (pl) * 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
US9090592B2 (en) * 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CN102675286B (zh) * 2011-03-07 2015-08-19 中国科学院上海药物研究所 一类吲唑类化合物及其制备方法、用途和药物组合物
WO2012136776A1 (en) * 2011-04-07 2012-10-11 Bayer Intellectual Property Gmbh Imidazopyridazines as akt kinase inhibitors
US9260425B2 (en) * 2011-08-12 2016-02-16 Genetech, Inc. Pyrazolo[3,4-c]pyridine compounds and methods of use
MY184882A (en) 2011-09-14 2021-04-29 Samumed Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors
EP2921494A1 (de) 2011-12-27 2015-09-23 Bayer Intellectual Property GmbH Heteroarylpiperidin und -piperazinderivate
BR112014018655B1 (pt) * 2012-02-21 2022-02-08 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A Composto de 1h-indazol-3-carboxamida, e, composição farmacêutica
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
DK2770994T3 (da) 2012-05-04 2019-11-11 Samumed Llc 1h-pyrazolo[3,4-b]pyridiner og terapeutiske anvendelser deraf
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
WO2014110086A2 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9440952B2 (en) 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
EP3010918B1 (en) * 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
KR20160135283A (ko) 2014-03-20 2016-11-25 사뮤메드, 엘엘씨 5-치환된 인다졸-3-카르복스아미드 및 이의 제조 및 용도
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
PE20171789A1 (es) * 2015-03-02 2017-12-28 Bristol Myers Squibb Co Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
PE20181175A1 (es) 2015-08-12 2018-07-20 Incyte Corp Sales de un inhibidor de lsd1
EP3371187A4 (en) 2015-11-06 2019-09-04 Samumed, LLC 2- (1H-INDAZOLE-3-YL) -3H-IMIDAZO [4,5-C] PYRIDINE AND ITS USE AS AN INHIBITOR OF INHIBITOR
US20170273307A1 (en) * 2016-03-28 2017-09-28 Trent University Silane-based antimicrobial coatings and methods of making and using the same
MA44725A (fr) 2016-04-22 2019-02-27 Incyte Corp Formulations d'un inhibiteur de lsd1
PL3464285T3 (pl) 2016-06-01 2023-02-06 Biosplice Therapeutics, Inc. Sposób wytwarzania n-(5-(3-(7-(3-fluorofenylo)-3h-imidazo[4,5-c]pirydyn-2-ylo)-1h-indazol-5-ilo)pirydyn-3-ylo)-3-metylobutanoamidu
RU2752088C1 (ru) 2016-09-21 2021-07-22 Вектус Байосистемс Лимитед Композиции для лечения гипертензии и/или фиброза
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CA3033249A1 (en) 2016-09-23 2018-03-29 Novartis Ag Indazole compounds for use in tendon and/or ligament injuries
CN110709082A (zh) 2016-10-21 2020-01-17 萨穆梅德有限公司 吲唑-3-甲酰胺的使用方法及其作为Wnt/β-连环蛋白信号传导途径抑制剂的用途
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
EA201991921A1 (ru) 2017-02-17 2020-02-06 Эйдос Терапьютикс, Инк. Способы получения ag-10, его промежуточных соединений и их солей
JP2020525525A (ja) * 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
ES2969536T3 (es) 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
MD3752510T2 (ro) 2018-02-15 2023-06-30 Vertex Pharma Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
TWI817999B (zh) 2018-03-23 2023-10-11 美商文涵治療有限公司 使用ag10治療ttr澱粉樣沉積症之方法
WO2019201297A1 (zh) * 2018-04-18 2019-10-24 南京明德新药研发有限公司 作为rho激酶抑制剂的苯并吡唑类化合物
BR112020026493A2 (pt) 2018-08-17 2021-03-23 Eidos Therapeutics, Inc. Formulações de ag10
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN111138426B (zh) * 2018-11-02 2023-03-10 安徽中科拓苒药物科学研究有限公司 吲唑类激酶抑制剂及其用途
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN110218694A (zh) * 2019-05-30 2019-09-10 华中农业大学 一种猕猴桃果实淀粉体提取方法
CN114599657A (zh) 2019-08-14 2022-06-07 弗特克斯药品有限公司 Cftr调节剂的结晶形式
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN111171023B (zh) * 2020-01-10 2021-12-21 中国药科大学 一种具有Pim1抑制活性的化合物及其制备方法与医药用途
CN113350347B (zh) * 2020-03-05 2023-07-04 安徽中科拓苒药物科学研究有限公司 吲唑类化合物的用途
CN116261452A (zh) * 2020-07-15 2023-06-13 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
WO2022076629A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN112266378B (zh) * 2020-11-09 2021-10-12 延边大学 含吲唑结构的咪唑类衍生物及其制备方法和应用
CN113336759B (zh) * 2020-12-25 2022-12-06 中国药科大学 溴结构域蛋白4小分子抑制剂、其制备方法及应用
CN117529475A (zh) * 2021-01-08 2024-02-06 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的含脲或类似物的杂双环化合物及其化合物
KR20230056824A (ko) * 2021-10-20 2023-04-28 전북대학교산학협력단 Pak4 저해제 및 그의 용도
WO2023186773A1 (en) 2022-03-30 2023-10-05 Nerviano Medical Sciences S.R.L. Substituted 3-amino indazole derivatives as kinase inhibitors
CN114651898B (zh) * 2022-03-31 2024-04-05 天津溢佳同惠科技集团有限公司 一种提高免疫力的三唑类饲料添加剂及其制备方法和应用
WO2023218201A1 (en) * 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
KR102607237B1 (ko) * 2023-06-07 2023-11-30 주식회사 젠센 신규한 트리아졸이 치환된 인다졸 유도체 및 이의 용도
CN116891460A (zh) * 2023-07-12 2023-10-17 浙江大学 一种吲唑类衍生物或其药用盐及应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2004013410A1 (en) * 2002-08-06 2004-02-12 Richard Stone Warp triplet composite forming fabric
WO2004031158A1 (fr) * 2002-10-02 2004-04-15 Sanofi-Aventis Derives d'indazolecarboxamides, leur preparation et leur utilisation comme inhibiteurs des cdk1, cdk2 et cdk4
WO2004039325A2 (en) * 2002-10-24 2004-05-13 Celgene Corporation Treatment of pain with jnk inhibitors
WO2005009997A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc. 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005099703A1 (fr) * 2004-03-16 2005-10-27 Sanofi-Aventis Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
RU2005121897A (ru) * 2002-12-12 2006-01-20 Авентис Фарма С.А. (Fr) Производные аминоиндазолов и их применение в качестве ингибиторов киназ
WO2006130297A2 (en) * 2005-04-29 2006-12-07 Celgene Corporation Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
DK1532145T3 (da) * 2002-08-02 2007-01-15 Vertex Pharma Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
WO2005074642A2 (en) * 2004-01-30 2005-08-18 Smithkline Beecham Corporation Chemical compounds
EP1742944B1 (en) * 2004-04-22 2010-11-10 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
DE102004028862A1 (de) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CN101102773B (zh) * 2004-12-27 2010-10-27 爱尔康公司 治疗青光眼和其他rho激酶-介导疾病的氨基吡嗪类似物
EP1945216A1 (en) * 2005-11-10 2008-07-23 Schering Corporation Methods for inhibiting protein kinases
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053268A2 (en) * 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
WO2004013410A1 (en) * 2002-08-06 2004-02-12 Richard Stone Warp triplet composite forming fabric
WO2004031158A1 (fr) * 2002-10-02 2004-04-15 Sanofi-Aventis Derives d'indazolecarboxamides, leur preparation et leur utilisation comme inhibiteurs des cdk1, cdk2 et cdk4
WO2004039325A2 (en) * 2002-10-24 2004-05-13 Celgene Corporation Treatment of pain with jnk inhibitors
RU2005121897A (ru) * 2002-12-12 2006-01-20 Авентис Фарма С.А. (Fr) Производные аминоиндазолов и их применение в качестве ингибиторов киназ
WO2005009997A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc. 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005099703A1 (fr) * 2004-03-16 2005-10-27 Sanofi-Aventis Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
WO2006130297A2 (en) * 2005-04-29 2006-12-07 Celgene Corporation Solid forms of 1-( 5-(ih-i , 2 , 4 -triazol- 5 -yl)(1h-indazol-3-yl))-3-(2-piperidylethoxy)benzene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEELA A. THOMAS et al. Identification of a novel 3,5-disubstituted pyridine as potent, selective, and orally active inhibitor of Aktl kinase. Bioorganic & Medicinal Chemistry Letters. 2006, 16, p.3740-3744. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2725979C2 (ru) * 2014-06-25 2020-07-08 Ф. Хоффманн-Ля Рош Аг ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
RU2750484C2 (ru) * 2016-12-01 2021-06-28 Эрвинэс Оперейшнс, Инк. Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
US11597720B2 (en) 2016-12-01 2023-03-07 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

Also Published As

Publication number Publication date
WO2008154241A1 (en) 2008-12-18
EP2167491A1 (en) 2010-03-31
JP5451602B2 (ja) 2014-03-26
IL202318A0 (en) 2010-06-30
AU2008262038A1 (en) 2008-12-18
JP2014074057A (ja) 2014-04-24
MX2009013213A (es) 2010-03-30
ZA200908624B (en) 2015-08-26
BRPI0811065A2 (pt) 2014-12-02
JP2010529137A (ja) 2010-08-26
KR20100032886A (ko) 2010-03-26
RU2009149696A (ru) 2011-07-20
SG182187A1 (en) 2012-07-30
CN101790526A (zh) 2010-07-28
CA2689117A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
RU2487873C2 (ru) 5-замещенные индазолы в качестве ингибиторов киназы
US9163007B2 (en) 5-substituted indazoles as kinase inhibitors
US11987560B2 (en) Inhibitors of lysine specific demethylase-1
JP6663866B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
DK2504333T3 (en) Morpholinothiazoler which alpha-7 positive allosteric modulators
EP3813819A1 (en) Inhibitors of cyclin-dependent kinases
US11891389B2 (en) PGDH inhibitors and methods of making and using
JP2019172676A (ja) リジン特異的なデメチラーゼ−１の阻害剤
EA025086B1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
EA036788B1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2013361255A1 (en) Histone demethylase inhibitors
AU2014298017B2 (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
JP2005530760A (ja) プロテインキナーゼモジュレーターおよびその使用方法
BRPI0713576A2 (pt) composto, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar condição, distúrbio e doença, para aumentar a formação óssea, para aumentar a formação óssea de estrutura esponjosa e/ou nova formação óssea, para aumentar a densidade mineral óssea, para reduzir a incidência de fratura e para melhorar a cicatrização de fratura, e, processo para preparar um composto
JP2011500815A (ja) トロパン化合物
DK2817302T3 (en) 1H-indazole-3-carboxamide compounds as glycogen synthase kinase-3 beta inhibitors
JP2013533318A (ja) ヘテロアリールおよびその使用
DK2817301T3 (en) Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase-3 beta inhibitors
AU2013231090A1 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
KR20240102934A (ko) 피롤로[2,3-b]피리딘 PGDH 억제제 그리고 제조 및 사용 방법
CA2959290A1 (en) 2-aminothiazole derivative or salt thereof

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20141128

MM4A The patent is invalid due to non-payment of fees

Effective date: 20150605